ITL Health Group (ASX:ITD) is continuing to build its portfolio of products within the lucrative $3.3b (and growing) global blood culture testing market. Its subsidiary ITL BioMedical launched its latest blood culture testing product earlier this year (March 2018) and there are plans to bring a further pipeline of new products to market in the current financial year.
Read More “Malaysian manufacturing unlocks global potential for high growth MedTechs”
ITL believes that Return on Investment is more than money, it is also about keeping its hard-working and highly trained staff happy. A recent article in CEO Magazine illustrates ITL BioMedical’s investment in employee satisfaction and retention.
Read More “ITL In The News: CEO Magazine: A medical device facility is taking a fresh approach to staff retention.”